Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy

Stephen Blake, Kimberley Stannard, Jing Liu, Stacey Allen, Michelle C.R. Yong, Deepak Mittal, Amelia Roman Aguilera, John J. Miles, Viviana P. Lutzky, Lucas Ferrari de Andrade, Ludovic Martinet, Marco Colonna, Kazuyoshi Takeda, Florian Kühnel, Engin Gurlevik, Günter Bernhardt, Michele W.L. Teng, Mark J. Smyth

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

CD96 has recently been shown as a negative regulator of mouse natural killer (NK)–cell activity, with Cd96-/- mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The antimetastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1), and IFN?, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti–CTLA-4, anti–PD-1, or doxorubicin chemotherapy. Blocking CD96 in Tigit-/- mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice. Co-blockade of CD96 and PD-1 potently inhibited lung metastases, with the combination increasing local NK-cell IFN? production and infiltration. Overall, these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases. Significance: This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96–CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade.

LanguageEnglish
Pages446-459
Number of pages14
JournalCancer Discovery
Volume6
Issue number4
DOIs
Publication statusPublished - 1 Apr 2016
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Cite this

Blake, S., Stannard, K., Liu, J., Allen, S., Yong, M. C. R., Mittal, D., ... Smyth, M. J. (2016). Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discovery, 6(4), 446-459. https://doi.org/10.1158/2159-8290.CD-15-0944
Blake, Stephen ; Stannard, Kimberley ; Liu, Jing ; Allen, Stacey ; Yong, Michelle C.R. ; Mittal, Deepak ; Aguilera, Amelia Roman ; Miles, John J. ; Lutzky, Viviana P. ; de Andrade, Lucas Ferrari ; Martinet, Ludovic ; Colonna, Marco ; Takeda, Kazuyoshi ; Kühnel, Florian ; Gurlevik, Engin ; Bernhardt, Günter ; Teng, Michele W.L. ; Smyth, Mark J. / Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. In: Cancer Discovery. 2016 ; Vol. 6, No. 4. pp. 446-459.
@article{eefb8fc5cd7043669dc077928c8f04ea,
title = "Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy",
abstract = "CD96 has recently been shown as a negative regulator of mouse natural killer (NK)–cell activity, with Cd96-/- mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The antimetastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1), and IFN?, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti–CTLA-4, anti–PD-1, or doxorubicin chemotherapy. Blocking CD96 in Tigit-/- mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice. Co-blockade of CD96 and PD-1 potently inhibited lung metastases, with the combination increasing local NK-cell IFN? production and infiltration. Overall, these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases. Significance: This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96–CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade.",
author = "Stephen Blake and Kimberley Stannard and Jing Liu and Stacey Allen and Yong, {Michelle C.R.} and Deepak Mittal and Aguilera, {Amelia Roman} and Miles, {John J.} and Lutzky, {Viviana P.} and {de Andrade}, {Lucas Ferrari} and Ludovic Martinet and Marco Colonna and Kazuyoshi Takeda and Florian K{\"u}hnel and Engin Gurlevik and G{\"u}nter Bernhardt and Teng, {Michele W.L.} and Smyth, {Mark J.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1158/2159-8290.CD-15-0944",
language = "English",
volume = "6",
pages = "446--459",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

Blake, S, Stannard, K, Liu, J, Allen, S, Yong, MCR, Mittal, D, Aguilera, AR, Miles, JJ, Lutzky, VP, de Andrade, LF, Martinet, L, Colonna, M, Takeda, K, Kühnel, F, Gurlevik, E, Bernhardt, G, Teng, MWL & Smyth, MJ 2016, 'Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy', Cancer Discovery, vol. 6, no. 4, pp. 446-459. https://doi.org/10.1158/2159-8290.CD-15-0944

Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. / Blake, Stephen; Stannard, Kimberley; Liu, Jing; Allen, Stacey; Yong, Michelle C.R.; Mittal, Deepak; Aguilera, Amelia Roman; Miles, John J.; Lutzky, Viviana P.; de Andrade, Lucas Ferrari; Martinet, Ludovic; Colonna, Marco; Takeda, Kazuyoshi; Kühnel, Florian; Gurlevik, Engin; Bernhardt, Günter; Teng, Michele W.L.; Smyth, Mark J.

In: Cancer Discovery, Vol. 6, No. 4, 01.04.2016, p. 446-459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy

AU - Blake, Stephen

AU - Stannard, Kimberley

AU - Liu, Jing

AU - Allen, Stacey

AU - Yong, Michelle C.R.

AU - Mittal, Deepak

AU - Aguilera, Amelia Roman

AU - Miles, John J.

AU - Lutzky, Viviana P.

AU - de Andrade, Lucas Ferrari

AU - Martinet, Ludovic

AU - Colonna, Marco

AU - Takeda, Kazuyoshi

AU - Kühnel, Florian

AU - Gurlevik, Engin

AU - Bernhardt, Günter

AU - Teng, Michele W.L.

AU - Smyth, Mark J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - CD96 has recently been shown as a negative regulator of mouse natural killer (NK)–cell activity, with Cd96-/- mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The antimetastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1), and IFN?, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti–CTLA-4, anti–PD-1, or doxorubicin chemotherapy. Blocking CD96 in Tigit-/- mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice. Co-blockade of CD96 and PD-1 potently inhibited lung metastases, with the combination increasing local NK-cell IFN? production and infiltration. Overall, these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases. Significance: This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96–CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade.

AB - CD96 has recently been shown as a negative regulator of mouse natural killer (NK)–cell activity, with Cd96-/- mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different tumor models. The antimetastatic activity of anti-CD96 was dependent on NK cells, CD226 (DNAM-1), and IFN?, but independent of activating Fc receptors. Anti-CD96 was more effective in combination with anti–CTLA-4, anti–PD-1, or doxorubicin chemotherapy. Blocking CD96 in Tigit-/- mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice. Co-blockade of CD96 and PD-1 potently inhibited lung metastases, with the combination increasing local NK-cell IFN? production and infiltration. Overall, these data demonstrate that blocking CD96 is a new and complementary immunotherapeutic strategy to reduce tumor metastases. Significance: This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96–CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=84962449276&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-0944

DO - 10.1158/2159-8290.CD-15-0944

M3 - Article

VL - 6

SP - 446

EP - 459

JO - Cancer Discovery

T2 - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 4

ER -